Breast Cancer Drug Discoveries

Summary

This report provides a comprehensive examination of all major breast cancer treatments, critical competitive evaluation of current and up and coming products and sales forecasts to 2014.

Unique market share sales forecasts by product to 2014

A comprehensive examination of all major breast cancer treatments

Critical competitive evaluation and scoring of current and up and coming products

The breast cancer (BC) market is a steadily growing market due to effective treatments which have decreased mortality and resulted in a longer duration of therapy. The five-year survival rates for women with BC have increased from under 70% 50 years ago to around 90% now. In 2007, we estimate that sales grew by 22% compared to 2006, generating revenue of over US$11.3 billion. Branded therapies were responsible for 92% of this total (US$10.5 billion).

In 2007, approximately 47% of BC sales were derived from the US, with 41% in Europe and 12% in Japan. Over the next six years we forecast that novel therapies including targeted monoclonal antibodies and small-molecule inhibitors, will increasingly be used in combination with chemotherapy and hormonal therapy.

The corporate landscape
Already the dominant force, throughout the next six to seven years Roche will continue to go from strength to strength, increasing its market share as its existing and future targeted therapies penetrate the BC market successfully. We believe the combination of Herceptin and pertuzumab has the potential to become the new standard of care in HER2-positive metastatic BC. Many of the existing players will be hit by generic competition over the coming 5 years, AstraZeneca, Novartis and sanofiaventis being notable.

REPORT CONTENTS SUMMARY

THE FACTS
Risk factors, how the disease affects patients, diagnosis and stages of the disease

PATIENT STATISTICS
Prevalence in the US, Europe and Japan
Diagnosis and treatment rates

THE MARKET
BC market split by US, Europe and Japan
Drug growth drivers/dampeners
The companies – market share 2007 and 2014

CURRENT TREATMENTS
Interventions by type
Unique five point competitive assessment of current therapies and companies involved
Sales forecasts by product 2007-2014

R&D: DRUGS IN PHASE II/III
Focus on new classes of drugs and the companies involved
Unique competitive assessment of current
therapies and companies involved

COMPETITOR ANALYSIS - PRODUCTS & COMPANIES
Winners and losers in the future

EXTENSIVE APPENDICES
Statistics on key areas such as patient population, launch probability

Contents

• Executive Summary
  • The Facts
    • What Is Bc And How Does It Affect Patients?
    • Risk Factors
    • Diagnosis
    • Stages Of The Disease
  • Patient Statistics
    • The Us
    • Europe
    • Japan
• Patient Model
  • The Prevalence Of People Living With Bc Will Increase By 26.6 Per Cent By 2014
• Drug Growth Drivers
• Drug Growth Risks/Dampeners
• The Breast Cancer Market
  • Bc Therapy Sales Split
  • Global Bc Sales Split
    • Us Market
    • European Market
    • Japanese Market
  • The Players
  • Players And Products In 2007
  • Players And Products In 2014
• Current Treatments
  • Surgery
  • Radiation
  • Hormonal Therapy
    • Leading Brands
    • Current Products' Patent Exposure
  • Chemotherapy
    • Leading Brands
    • Current Products' Patent Exposure
  • Molecular Targeted Therapy
    • Leading Brands
    • Curent Products' Patent Exposure
• Analysis Of Leading Brands
  • Hormonal Therapy
    • Anti-Oestrogen Drugs
    • Evista
    • Faslodex
    • Nolvadex
    • Aromatase Inhibitors
    • Arimidex
    • Aromasin
    • Femara
    • Lhrh Agonists
    • Zoladex
  • Chemotherapy
    • Taxanes
    • Abraxane
    • Taxol
    • Taxotere
    • Antimetabolites
    • Gemzar
    • Xeloda
    • Epothilone Analogues
    • Ixempra
  • Molecular Targeted Therapy
    • Avastin
    • Herceptin
    • Tykerb
• Sales Forecast Of Current Bc Drugs
• Research & Development Of Bc Drugs
• Analysis Of Phase Iii Drugs
  • Molecular Targeted Therapy
    • Angiogenesis Inhibitors
    • Armala
    • Imc-1121
    • B
    • Sutent
    • Her2/Neu Dimerisation Inhibitor
    • Pertuzumab
  • Hormonal Therapy
    • Arzoxifene
• Global Sales Forecasts Of Phase Iii Bc Drugs 2007a - 2014e
  • Model Assumptions
• Analysis Of Phase Ii Drugs
  • Molecular Targeted Therapy
    • Parp Inhibitors
    • Azd2281
    • Bsi-201
    • Therapeutic Vaccines
    • Ae37
    • Mva-Bn-Her2
    • Neuvax
    • Angiogenesis Inhibitor
    • Axitinib
    • Igf-1r Inhibitors
    • Ave1642
    • Imc-A12
    • Heat Shock Protein Inhibitors
    • Tanespimycin
    • Anti-Phospholipid Therapy
    • Bavituximab
  • Chemotherapy
    • Sagopilone
  • Hormonal Therapy
    • Zk-Pra
• Competitor Ratio Analysis
  • Competitor Ratio Analysis Criteria
• Competitor Ratio Analysis - Products
• Competitor Ratio Analysis - Companies
  • Winners & Losers
  • Winners
  • Losers
• Discontinuation Of Drugs
• Appendix 1: Diagnostic Assays
  • Her2 Diagnostics
  • virtual Cancer Patient Technology - Optimata
  • Brca Tests
  • Bc Detection
  • Future Advances In Diagnostics
• Appendix 2: Patient Model
• Appendix 3: Global Bc Drug Sales
• Appendix 4: Phase Transition Probability
• Glossary
• Bibliography
• Website References
• Acronyms
• Index Of Tables
  • Tmn Classification In Bc
  • Us Bc Statistics
  • European (Top 5 Countries) Bc Statistics
  • Japanese Bc Statistics
  • Summary Of Patient Population Forecasts In The Top 7 Countries (2007-2014e)
  • Current Major Hormonal Therapies
  • Comparison Of Leading Hormonal Therapies
  • Patent Exposure Of Leading Brands
  • Chemotherapy Combinations Currently Prescribed In Early-Stage Bc
  • Patent Exposure Of Leading Brands
  • Proposed Filings Of New Indications For Avastin
  • Global Sales Of Leading Bc Drugs 2007 A-2014 E (Us$ Millions)
  • Products In Clinical Development For The Treatment Of Bc
  • New Drugs In Phase Iii Development To Treat Bc
  • Sales Forecasts Of Phase Iii Developmental Bc Drugs (Us$ Million)
  • New Drugs In Phase Ii Development To Treat Bc
  • Key Bc Drugs On The Market By 2014
  • Company Competitor Ratio Analysis Scores
  • Summary Of Key Companies And Drugs In The Bc Market By 2014
  • Bc Drugs Discontinued During Development
  • Summary Of Us Bc Patient Population Forecasts
  • Summary Of European (Top 5) Bc Patient Population Forecasts
  • Summary Of Japanese Bc Patient Population Forecasts
  • Global Bc Drugs Sales 2007 A-2014
  • Probability Of Launch
• Index Of Charts
  • Schematic Of The Breast
  • Bc Market Opportunities
  • Impact Of Biomarker Identification On Bc Patients
  • Impact Of Biomarker Identification On Dose Selection Studies In Bc Patients
  • Global Bc Market By Therapy Class (2007 A)
  • Global Bc Market By Therapy Class (2014 E)
  • Global Sales Split By Region (2007)
  • Bc Us Drugs Sales Split (2007)
  • Market Share Of Bc Players By Sales (2007a)
  • Global Market Share Of Bc Players By Sales (Dec 2014e)
  • Schematic Of Treatment Options In Bc
  • Hormones Affecting Bc
  • Mode Of Action Of Anti-Oestrogens
  • Evista - Invasive Bc Incidence - Star Trial
  • Evista - Invasive Bc Placebo Trials
  • Evista Bc Sales (2007e-2014e)
  • Efect Trial Design - Fasoldex Vs Aromasin
  • Faslodex Sales (2005a-2014e)
  • Nolvadex Sales (2005a-2014e)
  • Mode Of Action Of Aromatase Inhibitors
  • Clinical Trial Data Drives Growth Of Bc Products
  • Arimidex Sales (2005a-2014e)
  • Pfizer's Broad Oncology Pipeline
  • Aromasin Sales (2005a-2014e)
  • Market Potential For Femara In Extended Adjuvant Setting
  • Femara Sales (2005a-2014e)
  • Zoladex Sales (2005a-2014e)
  • Clinical Efficacy Of Abraxane In Bc
  • Abraxane Bc Sales (2005a-2014e)
  • Taxol Bc Sales (2005a-2014e)
  • Taxotere Growth
  • Taxotere Bc Sales (2005a-2014e)
  • A) Time-To-Disease Progression And B) Overall Response Rate Of Metastatic Bc To Gemzar Treatment
  • Gemzar Bc Sales (2005a-2014e)
  • Xeloda Bc Sales (2005a-2014e)
  • Ixabepilone: Preclinical Synergy With Targeted Therapies
  • Ixempra Bc Sales (2007a-2014e)
  • Avastin Clinical Trials
  • Avastin Bc Sales (2007a-2014e)
  • Mechanism Of Action Of Herceptin
  • A) Herceptin Positive And Negative Bc Patient Split And B) Marketing Opportunities For Herceptin In Chemotherapy Patients
  • Herceptin Bc Sales (2005a-2014e)
  • Gsk To Target A Broad Bc Population With Tykerb
  • Bc Treatment Opportunities
  • Tykerb Sales (2007a-2014e)
  • Armala Bc Sales (2012e-2014e)
  • Imc-1121
  • B Bc Sales (2013e-2014e)
  • First-Line Phase Iii Bc Trial
  • Second/Third-Line Phase Iii Bc Trial
  • Pfizer's Bc Clinical Development Programme
  • Sutent Bc Sales (2012e-2014e)
  • Pertuzumab Bc Sales (2012e-2014e)
  • Arzoxifene Bc Sales (2010e-2014e)
  • The Role Of Hsp90 In Chaperoning Client Proteins
  • Company Competitor Ratio Analysis Scores